tbuckley/cabot-search huggingface dataset:
THU0271 High Correlation of RAPID-3 with DAS-28 Score as a Measure of Disease Activity in a Cohort of Colombian Patients with Rheumatoid Arthritis at Hospital Militar Central. BogotΆ, Colombia
Authors: J.E. Medina, G. Ballesteros, J.D. Londoño, R. Giraldo, A.M. Santos, R.R. Valle, J.M. Bello
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> RAPID-3 is a patient-driven tool to measure disease activity in rheumatoid arthritis (RA) without the need of laboratory test or the inclusion of a provider joint count and can be self reported by the patient.DAS-28 is a composite tool that needs patient, provider a laboratory information to measure disease activity <h3>Objectives</h3> To Asses the correlation of RAPID-3 and DAS-28 in a cohort of colombian patients with RA <h3>Methods</h3> 119 consecutive patients with early and established RA were evaluated at the Hospital Militar Central rheumatology service in Bogota-Colombia between August and December 2013. A complete medical history was obtained, including complete demographic information, comorbilities, concomitant medications and family history and laboratory tests. All patients completed a self reported RAPID-3 and were evaluated for a 28 swollen and painful joint count to obtain the DAS-28-ESR. Spearman correlations were computed for components of DAS28-ESR and RAPID3. <h3>Results</h3> 15,2 years). Mean scores were HAQ=0,6 (0,7), DAS28=3.8 (1.4) and RAPID3=12,3 (7.4). RAPID3 was strongly correlated with DAS28 (Spearman r:0.763, p&lt;0.001). <h3>Conclusions</h3> RAPID-3 had a good correlation with DAS-28. Furthermore it9s a self reported test and does not require an acute-phase reactant which makes it more atractive in a country with limited resources. <h3>References</h3> Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, et al. (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res 64: 640–7 Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (routine assessment of patient index data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. Journal of Rheumatology. 2008;35(11):2136–2147 <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5733
Clinical investigation of antiarrhythmic devices
Authors: Sanjeev Saksena, Andrew E. Epstein, Ralph Lazzara, James D. Maloney, Douglas P. Zipes, David G. Benditt, A. John Camm, Michael J. Domanski, John D. Fisher, Bernard J. Gersh, Gervasio A. Lamas, Michael H. Lehmann, Daniel E. Nickelson, Eric N. Prystowsky, D. George Wyse
Journal: Journal of the American College of Cardiology (1995)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Authors: Luca Richeldi, Roland M. du Bois, Ganesh Raghu, Arata Azuma, Kevin K. Brown, Ulrich Costabel, Vincent Cottin, Kevin R. Flaherty, David M. Hansell, Yoshikazu Inoue, Dong Soon Kim, Martin Kolb, Andrew G. Nicholson, Paul W. Noble, Moisés Selman, Hiroyuki Taniguchi, Michèle Brun, Florence Le Maulf, Mannaïg Girard, Susanne Stowasser, Rozsa Schlenker-Herceg, Bernd Disse, Harold R. Collard
Journal: New England Journal of Medicine (2014)

Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis.We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period.A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis.
Authors: S Rantapaa-Dahlqvist, S Wallberg-Jonsson, G Dahlen
Journal: Annals of the Rheumatic Diseases (1991)

Lipoprotein (a), (Lp(a)), an independent atherogenic factor, was significantly increased in 93 patients with classical, seropositive rheumatoid arthritis of median disease activity. In the patients with Lp(a) concentrations above the upper reference value of 480 mg/l there was a significant correlation between Lp(a) and the concentration of orosomucoid, erythrocyte sedimentation rate, and the platelet count. The plasma concentrations of cholesterol and high density lipoprotein-cholesterol in both male and female patients were significantly lower than in controls. Apolipoprotein B and apolipoprotein AI in the patients correlated significantly with total cholesterol and high density lipoprotein-cholesterol respectively.
STUDIES ON PNEUMOCOCCUS IMMUNITY
Authors: Russell L. Cecil, Gustav I. Steffen
Journal: The Journal of Experimental Medicine (1923)

1. Three subcutaneous injections of Pneumococcus Type II vaccine confer on monkeys a complete immunity against experimental Pneumococcus Type II pneumonia. A similar protection can be bestowed on monkeys against Pneumonococcus Type IV pneumonia by three subcutaneous injections of a vaccine prepared from the same strain of pneumococcus. 2. The subcutaneous injection of monkeys with three doses of Pneumococcus Type III vaccine confers a complete immunity against this type in only 50 per cent of cases (four out of eight monkeys vaccinated). 3. In spite of the immunity induced in monkeys by three subcutaneous injections of Pneumococcus Types II, III, and IV vaccine, specific protective bodies against the homologous types are not demonstrable in their serums when the vaccine is so administered.
Combinatorial Administration of Molecules That Simultaneously Inhibit Angiogenesis and Invasion Leads to Increased Therapeutic Efficacy in Mouse Models of Malignant Glioma
Authors: Lorenzo Bello, Valeria Lucini, Francesco Costa, Mauro Pluderi, Carlo Giussani, Francesco Acerbi, Giorgio Carrabba, Marilou Pannacci, Dario Caronzolo, Silvia Grosso, Svetlana Shinkaruk, Federica Colleoni, Xavier Canron, Giustino Tomei, Gerard Deleris, Andreas Bikfalvi
Journal: Clinical Cancer Research (2004)

Abstract Purpose: We investigated the ability of the combinatorial administration of different inhibitors with activities on glioma angiogenesis, migration, and proliferation to produce a prolonged inhibition of glioma growth. Experimental Design: We combined inhibitors affecting solely tumor angiogenesis (PF-4/CTF, cyclo-VEGI) or inhibitors affecting both angiogenesis and invasion together (PEX, PF-4/DLR). Results: When administered in combination, these drugs produced a prolonged and increased inhibition of glioma growth independently from the type of inhibitor used. The combinatory administration was more effective than the administration of a single inhibitor alone, and a strong therapeutic response was reached with a significantly lower amount of protein. The strongest inhibition was observed when human PEX and PF-4/DLR, which affect both glioma angiogenesis and invasion by separate mechanisms, were combined. Conclusions: This supports the concept that prolonged glioma growth inhibition can be achieved by simultaneous delivery of molecules that target both tumor and endothelial cells and acting by separate mechanisms.
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
Authors: Paul A. Hamlin, Andrew D. Zelenetz, Tarun Kewalramani, Jing Qin, Jaya M. Satagopan, David Verbel, Ariela Noy, Carol S. Portlock, David J. Straus, Joachim Yahalom, Stephen D. Nimer, Craig H. Moskowitz
Journal: Blood (2003)
Transition of care in children with chronic disease
Authors: Colin Wallis
Journal: BMJ (2007)

In upper airway obstruction (UAO) the relationship between the degree of obstruction, exercise limitation and lung function indices is not well established. Therefore, we investigated in nine healthy subjects (age 36+/-9 yrs) the effects of two added resistances at the mouth (R1 = added resistance with 7.8 mm diameter; R2 = 5.7 mm) on forced expiratory volume in one second (FEV1), peak expiratory flow (PEF), airway resistance (Raw) and maximal breathing capacity (measured during 15 s = measured maximum breathing capacity (MBCm); calculated as FEV1x37.5 = calculated maximum breathing capacity (MBCc)) on the one hand, and maximum exercise capacity (W9max), minute ventilation (V9E) and CO2 elimination (V9CO2) on the other. We found that R1 had almost no influence on FEV1 but decreased PEF by approximately 35% and increased Raw by almost 300%; it decreased W9max by merely approximately 10% while maximal exercise ventilation (V9Emax) was only 65% of control and only reached approximately 40% MBCc and approximately 70% MBCm; yet V9E and V9CO2 were significantly reduced at high exercise levels indicating hypoventilation. With R2, FEV1 was reduced by 25% and PEF by 55%, and Raw was increased by 600%; W9max was approximately 60% of control, V9Emax was only 35% of control and reached approximately 30% MBCc and approximately 60% MBCm, V9E was already reduced at moderate exercise levels. We conclude that: 1) an upper airway obstruction of 6 mm diameter (but not of 8 mm) had a marked influence on maximum exercise capacity due to hypoventilation; 2) calculated maximum breathing capacity markedly overestimated measured maximum breathing capacity because the forced expiratory volume in one second is an insensitive index of upper airway obstruction and because it does not take inspiratory flow limitation into account; and 3) a 10% decrease in maximum exercise capacity was linearly related with a 7% decrease in the forced expiratory volume in one second and a 150% increase in airway resistance. A 10% decrease in maximal exercise ventilation was related to a 8.5% decrease in peak expiratory flow and 9% decrease in measured maximum breathing capacity.
Effect of Palytoxin and Serotonin on Murine Tumor Cells<xref ref-type="fn" rid="fn2">2</xref>
Authors: S M El-Khatib, A M Preston
Journal: JNCI Journal of the National Cancer Institute (1979)

In vitro and in vivo effects of two fractions of a crude extract from the marine invertebrate Palythoa were investigated in Novikoff hepatoma and Ehrlich ascites tumor cells. These fractions, previously identified as serotonin and a partially purified toxin, inhibited thymidine incorporation into acid-precipitable material by tumor cells. Results from respiration studies indicated that the inhibitory effect was not toxic. The data suggested that: a) The partially purified toxin exerted its inhibitory effect at the membrane level; b) this inhibitory effect might have been accomplished through the Na+K+ transport mechanism, this conclusion being supported by data on the uptake of labeled amino acids by Ehrlich ascites tumor cells; and c) in an unconfirmed experiment, the partially purified toxin increased the survival time of 50% of 6 palytoxin-treated mice at least three times as long as 6 untreated control mice. All 12 mice had received 1 X 10(6) viable Ehrlich ascites tumor cells.
Age Affects Outcomes in Chronic Kidney Disease
Authors: Ann M. O'Hare, Andy I. Choi, Daniel Bertenthal, Peter Bacchetti, Amit X. Garg, James S. Kaufman, Louise C. Walter, Kala M. Mehta, Michael A. Steinman, Michael Allon, William M. McClellan, C. Seth Landefeld
Journal: Journal of the American Society of Nephrology (2007)

Chronic kidney disease (CKD) is common among the elderly. However, little is known about how the clinical implications of CKD vary with age. We examined the age-specific incidence of death, treated end-stage renal disease (ESRD), and change in estimated glomerular filtration rate (eGFR) among 209,622 US veterans with CKD stages 3 to 5 followed for a mean of 3.2 years. Patients aged 75 years or older at baseline comprised 47% of the overall cohort and accounted for 28% of the 9227 cases of ESRD that occurred during follow-up. Among patients of all ages, rates of both death and ESRD were inversely related to eGFR at baseline. However, among those with comparable levels of eGFR, older patients had higher rates of death and lower rates of ESRD than younger patients. Consequently, the level of eGFR below which the risk of ESRD exceeded the risk of death varied by age, ranging from 45 ml/min per 1.73 m(2) for 18 to 44 year old patients to 15 ml/min per 1.73 m(2) for 65 to 84 year old patients. Among those 85 years or older, the risk of death always exceeded the risk of ESRD in this cohort. Among patients with eGFR levels <45 ml/min per 1.73 m(2) at baseline, older patients were less likely than their younger counterparts to experience an annual decline in eGFR of >3 ml/min per 1.73 m(2). In conclusion, age is a major effect modifier among patients with an eGFR of <60 ml/min per 1.73 m(2), challenging us to move beyond a uniform stage-based approach to managing CKD.
Helium-Hyperoxia, Exercise, and Respiratory Mechanics in Chronic Obstructive Pulmonary Disease
Authors: Neil D. Eves, Stewart R. Petersen, Mark J. Haykowsky, Eric Y. Wong, Richard L. Jones
Journal: American Journal of Respiratory and Critical Care Medicine (2006)

Hyperoxia and normoxic helium independently reduce dynamic hyperinflation and improve the exercise tolerance of patients with chronic obstructive pulmonary disease (COPD). Combining these gases could have an additive effect on dynamic hyperinflation and a greater impact on respiratory mechanics and exercise tolerance.To investigate whether helium-hyperoxia improves the exercise tolerance and respiratory mechanics of patients with COPD.Ten males with COPD (FEV(1) = 47 +/- 17%pred [mean +/- SD]) performed randomized constant-load cycling at 60% of maximal work rate breathing air, hyperoxia (40% O(2), 60% N(2)), normoxic helium (21% O(2), 79% He), or helium-hyperoxia (40% O(2), 60% He).Exercise time, inspiratory capacity (IC), work of breathing, and exertional symptoms were measured with each gas.Compared with air (9.4 +/- 5.2 min), exercise time was increased with hyperoxia (17.8 +/- 5.8 min) and normoxic helium (16.7 +/- 9.1 min) but the improvement with helium-hyperoxia (26.3 +/- 10.6 min) was greater than both these gases (p = 0.019 and p = 0.007, respectively). At an isotime during exercise, all three gases reduced dyspnea and both helium mixtures increased IC and tidal volume. Only helium-hyperoxia significantly reduced the resistive work of breathing (15.8 +/- 4.2 vs. 10.1 +/- 4.1 L . cm H(2)O(-1)) and the work to overcome intrinsic positive end-expiratory pressure (7.7 +/- 1.9 vs. 3.6 +/- 2.1 L . cm H(2)O(-1)). At symptom limitation, tidal volume remained augmented with both helium mixtures, but IC and the work of breathing were unchanged compared with air.Combining helium and hyperoxia delays dynamic hyperinflation and improves respiratory mechanics, which translates into added improvements in exercise tolerance for patients with COPD.
Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular Events
Authors: Aileen M. Healy, Michael D. Pickard, Aruna D. Pradhan, Yunmei Wang, Zhiping Chen, Kevin Croce, Masashi Sakuma, Can Shi, Alexandre C. Zago, Joseph Garasic, Andrew I. Damokosh, Tracy L. Dowie, Louis Poisson, James Lillie, Peter Libby, Paul M Ridker, Daniel I. Simon
Journal: Circulation (2006)

Background— Platelets participate in events that immediately precede acute myocardial infarction. Because platelets lack nuclear DNA but retain megakaryocyte-derived mRNAs, the platelet transcriptome provides a novel window on gene expression preceding acute coronary events. Methods and Results— We profiled platelet mRNA from patients with acute ST-segment–elevation myocardial infarction (STEMI, n=16) or stable coronary artery disease (n=44). The platelet transcriptomes were analyzed and single-gene models constructed to identify candidate genes with differential expression. We validated 1 candidate gene product by performing a prospective, nested case-control study (n=255 case-control pairs) among apparently healthy women to assess the risk of future cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death) associated with baseline plasma levels of the candidate protein. Platelets isolated from STEMI and coronary artery disease patients contained 54 differentially expressed transcripts. The strongest discriminators of STEMI in the microarrays were CD69 (odds ratio 6.2, P &lt;0.001) and myeloid-related protein-14 (MRP-14; odds ratio 3.3, P =0.002). Plasma levels of MRP-8/14 heterodimer were higher in STEMI patients (17.0 versus 8.0 μg/mL, P &lt;0.001). In the validation study, the risk of a first cardiovascular event increased with each increasing quartile of MRP-8/14 ( P trend &lt;0.001) such that women with the highest levels had a 3.8-fold increase in risk of any vascular event ( P &lt;0.001). Risks were independent of standard risk factors and C-reactive protein. Conclusions— The platelet transcriptome reveals quantitative differences between acute and stable coronary artery disease. MRP-14 expression increases before STEMI, and increasing plasma concentrations of MRP-8/14 among healthy individuals predict the risk of future cardiovascular events.
Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period
Authors: W O Rohof, R J Bennink, A A de Ruigh, D P Hirsch, A H Zwinderman, G E Boeckxstaens
Journal: Gut (2012)

The risk for acidic reflux is mainly determined by the position of the gastric acid pocket. It was hypothesised that compounds affecting proximal stomach tone might reduce gastro-oesophageal reflux by changing the acid pocket position.To study the effect of azithromycin (Azi) on acid pocket position and acid exposure in patients with gastro-oesophageal reflux disease (GORD).Nineteen patients with GORD were included, of whom seven had a large hiatal hernia (≥3 cm) (L-HH) and 12 had a small or no hiatal hernia (S-HH). Patients were randomised to Azi 250 mg/day or placebo during 3 days in a crossover manner. On each study day, reflux episodes were detected using concurrent high-resolution manometry and pH-impedance monitoring after a standardised meal. The acid pocket was visualised using scintigraphy, and its position was determined relative to the diaphragm.Azi reduced the number of acid reflux events (placebo 8.0±2.2 vs Azi 5.6±1.8, p<0.01) and postprandial acid exposure (placebo 10.5±3.8% vs Azi 5.9±2.5%, p<0.05) in all patients without affecting the total number of reflux episodes. Acid reflux occurred mainly when the acid pocket was located above, or at the level of, the diaphragm, rather than below the diaphragm. Treatment with Azi reduced hiatal hernia size and resulted in a more distal position of the acid pocket compared with placebo (below the diaphragm 39% vs 29%, p=0.03). Azi reduced the rate of acid reflux episodes in patients with S-HH (38% to 17%) to a greater extent than in patients with L-HH (69% to 62%, p=0.04).Azi reduces acid reflux episodes and oesophageal acid exposure. This effect was associated with a smaller hiatal hernia size and a more distal position of the acid pocket, further indicating the importance of the acid pocket in the pathogenesis of GORD.http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1970 NTR1970.
Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study
Authors: R. Yerushalmi, M.R. Kramer, S. Rizel, A. Sulkes, K. Gelmon, T. Granot, V. Neiman, S.M. Stemmer
Journal: Annals of Oncology (2009)

Prompted by complaints of dyspnea in breast cancer patients receiving adjuvant dose-dense chemotherapy (DDC), we sought to evaluate the possible association of DDC with pulmonary dysfunction.A total of 34 consecutive patients receiving adjuvant DDC were enrolled. The chemotherapy regimen consisted of i.v. doxorubicin 60 mg/m(2) and cyclophosphamide 600 mg/m(2) (AC) every 14 days x4 with growth factor support followed by weekly i.v. paclitaxel 80 mg/m(2) x12. The following parameters were prospectively measured before and after the AC protocol (P1, P2) and at completion of paclitaxel treatment (P3): presence of dyspnea, blood pressure, pulse rate, hemoglobin, erythrocyte sedimentation rate, C-reactive protein level, cardiac ejection fraction, and pulmonary function. Repeated measures analysis was used to evaluate differences among the time points, and paired t-test was used to evaluate differences between consecutive time points.Although only five patients (15%) complained of dyspnea, there was a significant decrease in mean carbon monoxide diffusing capacity (DLCO), in all patients from P1 (22.09 ml/min/mmHg) to P3 (15 ml/min/mmHg) and in 29 of 32 patients (90.6%) from P1 to P2 (15.96 ml/min/mmHg) (P<0.001).DDC is associated with a statistical significant reduction in DLCO. Awareness of this potential toxicity may be important in women with preexisting lung disease.